Rani Therapeutics Holdings, Inc. (NASDAQ: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics, today announced a Collaboration and License Agreement with Chugai Pharmaceutical Co., Ltd., valued at up to $1.085 billion if all milestones and options are fully realized. In a separate announcement, Rani also disclosed an oversubscribed $60.3 million private placement financing led by Samsara BioCapital with participation from RA Capital Management, Anomaly, Special Situations Funds, Invus, and Rani founder and chairman Mir Imran.

Under the terms of the agreement, Rani will combine its proprietary RaniPill® oral delivery technology with one of Chugai’s rare-disease antibodies in development. Rani will receive an up-front payment of $10 million and will be eligible for up to $75 million in technology-transfer and development milestones, up to $100 million in sales-based milestones, and single-digit royalties on future product sales.Chugai also holds options to expand the collaboration to as many as five additional drug targets under similar financial terms. If all options are exercised, the total potential value of the collaboration could reach approximately $1.085 billion.

“This partnership represents a convergence of Rani’s cutting-edge oral-delivery platform and Chugai’s expertise in antibody research and commercialization,” said Talat Imran, Chief Executive Officer of Rani Therapeutics. “We are uniting two scientific teams to advance an oral therapy with the potential to transform treatment for patients living with rare and immunologic diseases.”

Dr. Tomoyuki Igawa, Vice President and Head of Research Division at Chugai, added: “Rani’s innovative technology opens new possibilities for biologics traditionally limited to injections. By integrating our proprietary antibody-engineering expertise with Rani’s platform, we aim to create patient-friendly oral therapies that reduce treatment burden and improve adherence.”

Rani has entered into a securities purchase agreement for a private placement expected to yield gross proceeds of approximately $60.3 million. The company said that the proceeds from this financing... together with the up-front payment and anticipated $18 million in early technology-transfer milestones from Chugai… are expected to fund operations into 2028. Following the announcement, shares of Rani Therapeutics surged more than 140% in pre-market trading on Friday. Investors cited the Chugai partnership as a significant validation of Rani’s oral biologics platform and its growing relevance in rare-disease and immunology markets.

About Rani Therapeutics Holdings, Inc.

Rani Therapeutics (NASDAQ: RANI) is a clinical-stage biotherapeutics company developing technologies to enable the oral delivery of biologics and drugs. The company’s proprietary RaniPill® capsule is designed to replace injections with an oral approach that simplifies treatment and improves patient adherence. Rani is headquartered in San Jose, California.

About Chugai Pharmaceutical Co., Ltd.

Chugai Pharmaceutical Co., Ltd., a member of the Roche Group, is a leading Japanese biotechnology company specializing in the research, development, manufacture, and marketing of innovative therapies in oncology, immunology, and rare diseases. The company is headquartered in Tokyo, Japan.

At the time of publishing, Stocks.News does not hold positions in companies mentioned in the article.